{"path":"Images/Pasted image 20240430094353.png","text":"Dexmedetomidine Clonidine Figure 4. Dexmedetomidine and cloni- T dine. Dexmedetomidine- and clonidine- o et induced antinociception occur primarily ° . ° ,\" through enhanced inhibitory activity in I i / the descending nociceptive pathways. Cortex , ILNI 4 Sedati(_)n_ induced by dexmede_tomidine (yé) (I)E) e or clonidine and loss of consciousness | induced by dexmedetomidine occur (-] i POA (Gal/GABA) through ~ NE-mediated disinhibition N H VPAG | of the POA of the hypothalamus and Basal | ’ ) 4 ®.LOT/PPT (AGH) | decreased noradrenergic_signaling in forebrajn ‘( ¥ oyE) L‘.e Q | the thalamus and cortex. 5HT indicates TMN (His) | serotonin; ACh, acetylcholine; DA, dopa- | Suey | mine; DR, dorsal raphé; DRG, dorsal \\ | ‘ root ganglia; GABA,, y-aminobutyric acid Clonidine W e | receptor subtype A; Gal, galanin; His, vp? ‘.‘ (f)’é) LC | histamine; ILN, intralaminar nucleus of P o (NE) the thalamus; LC, locus coeruleus; LDT, DRG e laterodorsal tegmental area; NE, norepi- v, ﬂ nephrine; PAF, peripheral afferent fiber; PN PN, projection neuron; POA, preoptic : RVM area; PPT, pedunculopontine tegmen- S | tal area; RVM, rostral ventral medulla; = -. i TMN, tuberomammillary nucleus; vPAG, e ventral periaqueductal gray.","libVersion":"0.3.2","langs":"eng"}